Scientific Sessions
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Resources
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter iconFacebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 16th, 2020

Session highlights discoveries in myocardial regeneration


Getty Images 1283608642

Potential treatment strategies to repair the heart are emerging through clinical studies, said presenters in Monday’s “New Frontiers in Myocardial Regeneration” session.

The session featured advances in various myocardial regeneration approaches and possible mechanisms of regeneration by applying animal models to human biology and novel strategies.

“Bringing a drug to market is expensive because the animal model and simple human cell culture are not a good predictor of human physiology,” said Gordana Vanjak-Novakovic, PhD, the University and Miakti Foundation professor of biomedical engineering and medical sciences laboratory for stem cells and tissue engineering at Columbia University in New York City.

Dr. Vanjak-Novakovic discussed how a novel research platform for engineering human myocardium, “organs on a chip,” involves bioengineering and maturing tissue on physical platforms, designed to emulate human physiology, can provide more relevant results to actual humans.

“We design the environments, and cells do the engineering,” she said.

Using a Google map as an analogy, Li Qian, PhD, described how she and her team at the McAllister Heart Institute at the University of North Carolina at Chapel Hill Direct are using single cell “transcriptonomics” and mathematical modeling to reconstruct the molecular roadmap of cardiac reprogramming to ultimately convert cardiac fibroblasts into cardiomyocyte-like cells.

“We hope to treat cardiac fibroblasts to create personalized treatments for myocardial infarction,” she said.

In her four vignettes about cardiac repair, Nadia Rosenthal, PhD, scientific director of The Jackson Laboratory in Bar Harbor, Maine, also presented insight into the complexity of myocardial regeneration.

“Cardiac cellular composition is dynamic, sexually dimorphic and altered by stress/damage signals,” she said.

Moreover, cardiac fibroblasts retain a regional code of morphogenetic gene expression, possibly for tissue repair. Her research reveals that immune interstitial signaling circuits provide important novel entry points for improving repair.

“Cardiac repair as a genetically tractable trait offers prospects for mapping gene networks and therapeutic targets,” she said.

Mauro Giacca, MD, PhD, professor of cardiovascular sciences in the School of Cardiovascular Medicine & Sciences at King’s College in London, presented his research on lipid-based nanoparticle (LNP) microRNA (miRNA) networks.

“Throughout life, we continue to lose cardiomyocytes,” he said. “All the drugs we have only target the capacity of the residual myocytes to improve their function. New treatments are needed to generate new cardiomyocytes. We have two options: Implant newer cells from the outside or try to convince surviving cardiomyocytes to proliferate.”

Dr. Giacca described how LNPmiRNA therapy delivered via intramyocardial injection may be able to transform non-cardiomyocytes into proliferating cells.

“The idea of using LNP-miRNA for cardiac regeneration is possible,” he said. “Even if you gain 10% to 20% ejection fraction, that can prevent heart failure.”

Jeff D. Molkentin, PhD, director of the division of Molecular Cardiovascular Biology at Cincinnati Children’s in Ohio, concluded the session with an overview of his research on myocardial cell therapy for myocardial cell rejuvenation: Injecting bone marrow mononuclear cells into the heart induces endothelial cell activity and new vascular genesis.  

His research suggests that the acute sterile immune response from the injection therapy induces angiogenesis in the heart at injection sites, reconditions the extracellular membrane and reduces border zone fibrosis expansion.

“It’s all just wound-healing biology,” Dr. Molkentin said.

 

Interesting Stories
Data-driven precision medicine
Sponsored by Tempus
Data-driven precision medicine
Modern Wearable Defibrillation
Sponsored by Kestra Medical Technologies
Modern Wearable Defibrillation
New Double Take Videos from NEJM
Sponsored by NEJM Group
New Double Take Videos from NEJM
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Sponsored by MiCare Path
MiCare Path joins the AHA CHTI and will integrate AHA science-based
More Content
puppy snugglers
AHA22
Special Recognition to the Hinsdale Humane Society
Nov 8th, 2022
LBS 05 panelists
AHA22
Trials’ results highlight supplement ineffectiveness and potential for novel therapies to lower lipoprotein(a), reduce CKD progression
Nov 8th, 2022
Panelists of the Mindful Disruption panel
Late-Breaking Science
Overcoming health disparities, health care advocates and mindfulness can better manage BP and CVD
Nov 7th, 2022
Medtech
AHA22
Medtech is getting smarter — and so is patient care
Nov 7th, 2022
med tech checking fluids in a hospital
AHA22
New digital hub offers professional education to complement lifelong learning
Nov 7th, 2022
AHA speaker dais
AHA22
Uncovering novel approaches in heart failure science
Nov 7th, 2022
22 Aha Tb 007061 (1)
AHA22
Sharing the good
Nov 6th, 2022
Dr. Duflo's headshot
AHA22
Paul Dudley White International Lecture explores link between poverty, COVID-19 and CVD risk
Nov 6th, 2022
Wifiheart Base
AHA22
Stay connected
Nov 1st, 2022
Headshots of Harriette Van Spall and Erica Gunderson
AHA22
Harriette Van Spall and Erica Gunderson honored with the Dr. Nanette K. Wenger Research Goes Red® Award
Nov 1st, 2022
Lansing page for virtual platform
AHA22
Watch: Scientific Session Virtual Platform tour
Nov 1st, 2022
Christine E. Seidman, MD, FAHA,
AHA22
Christine E. Seidman to Receive the 2022 Research Achievement Award
Oct 27th, 2022